DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for ectropion — screening already-approved drugs against its 10-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEctropion maps to a 10-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ectropion is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phospholipase A2 group IIA (PLA2G2A) — PLA2G2A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 5'-benzyl-2'-carbamoylbiphenyl-3-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5G3N · 1.8 Å · ligand 3-(5'-BENZYL-2'-CARBAMOYLBIPHENYL-3-YL)PROPANOIC ACID (X28). Experimental structure, not a prediction.
What the evidence adds up to
A 2019 literature review of cicatricial ectropion catalogues multiple causes: systemic diseases such as ichthyosis and lupus erythematosus, reversible cases linked to anti-glaucomatous drugs, and more recently reported associations with periorbital necrotising fasciitis, frontal osteomyelitis, and antineoplastic agents. The authors stress that determining the real aetiology is imperative for proper management and that a multidisciplinary approach is essential, especially for systemic conditions. No patient numbers, response rates, or survival data are given; the paper is a narrative review, not a clinical trial.
A 2004 case report describes a Brazilian patient with congenital ectropion uveae who carries the R1748X mutation in the NF1 gene. Congenital ectropion uveae is a rare, nonprogressive anomaly in which iris pigment epithelium appears on the anterior iris stroma; it is occasionally associated with Rieger’s anomaly, Prader-Willi syndrome, and neurofibromatosis type 1. The most important complication is congenital or juvenile glaucoma. This is the third report in the literature linking ectropion to neurofibromatosis. The authors suggest that if the association is confirmed, NF1 patients should be examined for ectropion and consequently for glaucoma risk. No treatment or drug is tested.
No drug is proposed or tested for ectropion in any of these abstracts. The 2019 review notes that some drug-induced cases are reversible upon stopping the offending agent, but it does not name a specific drug for repurposing. The 2004 report is purely genetic and diagnostic. What is missing is any controlled trial of a therapeutic intervention, any patient stratification by ectropion subtype, and any funding for a treatment study. Without such evidence, no drug can be recommended.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Arquivos Brasileiros de Oftalmologia · 2019 · 8 citations · open access
Diseases, conditions, and drugs associated with cicatricial ectropion
AbstractCicatricial ectropion may be a consequence of certain systemic diseases as well as the result of drug use. Our goal here was to research the different causes of this condition as reported in the literature, including more recently suspected etiologies. A detailed PubMed literature search indicated many different etiologies were associated with cicatricial ectropion development, from severe cases of systemic diseases, such as ichthyosis and lupus erythematosus, to reversible scenarios secondary to anti-glaucomatous drug use. More recently reported connections include periorbital necrotizing fasciitis, frontal osteomyelitis, and antineoplastic agents. Indeed, cicatricial ectropion may be highly symptomatic; being able to determine its real etiology is imperative to managing patients properly. In this investigation, we felt that an explicitly multidisciplinary approach was essential, especially for cases associated with systemic conditions.
Presence of the R1748X Mutation in the <i>NF1</i> Gene in a Brazilian Patient with Ectropion uveae
AbstractCongenital ectropion uveae is a rare, nonprogressive anomaly characterized by the presence of iris pigment epithelium on the anterior surface of the iris stroma and is occasionally associated with Rieger's anomaly, Prader-Willi syndrome and neurofibromatosis type 1 (NF1). The most important complication of ectropion uveae is congenital or juvenile glaucoma. We described a patient with ectropion and the mutation R1748X in the NF1 gene. This is the third report in the literature describing ectropion associated with neurofibromatosis. If this association is confirmed by other authors, the NF1 patients should be examined for the presence of ectropion and, consequently, for the development of glaucoma.
Diseases, conditions, and drugs associated with cicatricial ectropion
AbstractABSTRACT Cicatricial ectropion may be a consequence of certain systemic diseases as well as the result of drug use. Our goal here was to research the different causes of this condition as reported in the literature, including more recently suspected etiologies. A detailed PubMed literature search indicated many different etiologies were associated with cicatricial ectropion development, from severe cases of systemic diseases, such as ichthyosis and lupus erythematosus, to reversible scenarios secondary to anti-glaucomatous drug use. More recently reported connections include periorbital necrotizing fasciitis, frontal osteomyelitis, and antineoplastic agents. Indeed, cicatricial ectropion may be highly symptomatic; being able to determine its real etiology is imperative to managing patients properly. In this investigation, we felt that an explicitly multidisciplinary approach was essential, especially for cases associated with systemic conditions.
Diseases, conditions, and drugs associated with cicatricial ectropion
AbstractABSTRACT Cicatricial ectropion may be a consequence of certain systemic diseases as well as the result of drug use. Our goal here was to research the different causes of this condition as reported in the literature, including more recently suspected etiologies. A detailed PubMed literature search indicated many different etiologies were associated with cicatricial ectropion development, from severe cases of systemic diseases, such as ichthyosis and lupus erythematosus, to reversible scenarios secondary to anti-glaucomatous drug use. More recently reported connections include periorbital necrotizing fasciitis, frontal osteomyelitis, and antineoplastic agents. Indeed, cicatricial ectropion may be highly symptomatic; being able to determine its real etiology is imperative to managing patients properly. In this investigation, we felt that an explicitly multidisciplinary approach was essential, especially for cases associated with systemic conditions.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
